Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin therapies may facilitate clinically significant weight loss and improved cardiometabolic outcomes.
- These therapies are associated with a reduction in dietary intake.
- Gastrointestinal symptoms may occur during treatment.
- There is a potential loss of lean mass linked to the use of these therapies.
- Micronutrient deficiencies could arise as a consequence of treatment.
- Weight regain may occur after discontinuation of these therapies.
Simplified